Susan Pandya

Susan Pandya

Head of Cancer Metabolism Global Development Oncology & Immuno-Oncology

Susan Pandya M.D., is the Head of Cancer Metabolism Global Development Oncology & Immuno-Oncology at Servier Pharmaceuticals. She leads Servier’s Oncology clinical development from early clinical studies to pivotal phase 3 programs and successful FDA approvals, including TIBSOVO® (ivosidenib tablets)’s supplemental approval for advanced or metastatic cholangiocarcinoma in 2021, newly diagnosed acute myeloid leukemia (AML) in 2022 and relapsed or refractory (R/R) myelodysplastic syndromes (MDS) in 2023. Her leadership also extends to early and late phase clinical development of vorasidenib, including the pivotal Phase 3 INDIGO trial for vorasidenib, which was selected for a plenary at ASCO 2023 and is currently under review by the U.S. FDA and European Commission for the treatment of IDH-mutant diffuse glioma.

She is a passionate and innovative oncologist with over a decade of oncology drug development experience in both academic and biotech settings. Prior to Servier, she led the Oncology Clinical Development at Agios Pharmaceuticals. Earlier in her career, she led the development of early-stage oncology and muscle disease assets at Acceleron Pharma.

Susan earned her Doctor of Medicine from Tufts University School of Medicine and completed her residency in internal medicine and fellowship in Hematology/Oncology at the Beth Israel Deaconess Medical Center (BIDMC), a Harvard University teaching hospital. She continued her career as a board certified Hematologist/Oncologist at BIDMC with a focus on early phase clinical development as the Associate Director of the Phase 1 experimental therapeutics program, while maintaining a clinical practice in GI and Breast Oncology where she mentored medical students, residents and fellows in training.